ALK and ROS1 rearrangement in NSCLC : rapidly evolving standards

Mené sur 54 patients atteints d'un cancer du poumon non à petites cellules avec réarrangement du gène ALK ou ROS, cet essai international de phase I évalue les toxicités limitant la dose de lorlatinib lors du premier cycle thérapeutique

Résumé en anglais

Approximately 5% of patients with non-small-cell lung cancer (NSCLC) have a rearrangement in the gene for anaplastic lymphoma kinase (ALK), an oncogenic fusion protein.1 Crizotinib, alectinib, and ceritinib are tyrosine kinase inhibitors (TKIs) used for untreated, ALK-positive patients. Crizotinib was approved as frontline therapy based on results showing longer progression-free survival (10·9 months [95% CI 8·3–13·9]) than that seen with platinum-based chemotherapy (7·0 months [95% CI 6·8–8·2]; hazard ratio [HR] for progression or death 0·45, 95% CI 0·35–0·60; p<0·001).